Lung Cancer Clinical Trials

Showing 3501-3520 of 4,288 trials

ZD6474(Vandetanib) + Alimta Combo Study

NCT00506051

The main purpose of this trial is to look to see if adding ZD6474 (100 mg or 300mg tablets) to Alimta chemotherapy in patients with non-small cell lung cancer is safe and will help control their symptoms and disease better than the chemotherapy alone.

CarcinomaNon-Small Cell LungLung Cancer

Genzyme, a Sanofi Company21 participantsStarted Jul 2005

COMPLETEDPhase 2

ZD6474 in Treating Patients With Small Cell Lung Cancer

NCT00066313

RATIONALE: ZD6474 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. ZD6474 may also stop the growth of small cell lung cancer by blocking blood flow to the tumor. PURPOSE: This randomized phase II trial is studying how well ZD6474 works compared to placebo in treating patients with small cell lung cancer that has responded to previous chemotherapy with or without radiation therapy.

Lung Cancer

Genzyme, a Sanofi CompanyStarted May 2003

Calgary, Alberta, Canada • Edmonton, Alberta, Canada • Kelowna, British Columbia, Canada +18 more locations

ZD6474(Vandetanib) + Alimta Combo Study

ZD6474 in Treating Patients With Small Cell Lung Cancer

Related Searches

Apatinib as the Maintenance Therapy for Extensive Stage Small Cell Lung Cancer After Combined With Etoposide/Cisplatin

Registry Study of Thoracic Reirradiation for Non-Small Cell Lung Cancer (NSCLC) Utilizing Proton Beam Therapy or Intensity Modulated Radiation Therapy

Feasibility Study to Estimate Number of Patients With Precancerous Areas in Their Airways and the Response to Gefitinib

Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies

Early Lung Cancer Detection Using Computed Tomography

Irinotecan, Carboplatin and Radiation Therapy Followed by Bevacizumab in Limited Stage Small Cell Lung Cancer

Lepirudin in Treating Patients With Recurrent or Advanced Small Cell Lung Cancer

T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies

Temozolomide for Relapsed Sensitive or Refractory Small Cell Lung Cancer

Phase 2 Trial of Durvalumab With or Without Bavituximab in Patients With Previously Treated Metastatic Non-small-cell Lung Cancer

Immunotherapy With Racotumomab in Advanced Lung Cancer

Radiotherapy Dose Complement in the Treatment of Hypoxic Lesions Patients With Stage III Non-small-cell Lung Cancer

Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung Cancer

Intensity-modulated Radiotherapy (IMRT) With Simultaneous Integrated Boost (SIB) for Inoperable Non-small-cell Lung Cancer

Gemcitabine Plus Docetaxel or Irinotecan in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer

Chemotherapy Plus Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer

Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer